Literature DB >> 26611604

Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Dominic J Gessler1, Guangping Gao2.   

Abstract

Metabolic disorders comprise a large group of heterogeneous diseases ranging from very prevalent diseases such as diabetes mellitus to rare genetic disorders like Canavan Disease. Whether either of these diseases is amendable by gene therapy depends to a large degree on the knowledge of their pathomechanism, availability of the therapeutic gene, vector selection, and availability of suitable animal models. In this book chapter, we review three metabolic disorders of the central nervous system (CNS; Canavan Disease, Niemann-Pick disease and Phenylketonuria) to give examples for primary and secondary metabolic disorders of the brain and the attempts that have been made to use adeno-associated virus (AAV) based gene therapy for treatment. Finally, we highlight commonalities and obstacles in the development of gene therapy for metabolic disorders of the CNS exemplified by those three diseases.

Entities:  

Keywords:  AAV; CNS; Canavan’s disease; Gene therapy; Metabolic disorder s; Niemann–Pick disease; Phenylketonuria; Retrovirus

Mesh:

Year:  2016        PMID: 26611604      PMCID: PMC4961359          DOI: 10.1007/978-1-4939-3271-9_30

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  176 in total

1.  Experimentally induced and natural recovery from the effects of phenylalanine on brain protein synthesis.

Authors:  J V Hughes; T C Johnson
Journal:  Biochim Biophys Acta       Date:  1978-02-16

2.  Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system.

Authors:  K Kitada; T Akimitsu; Y Shigematsu; A Kondo; T Maihara; N Yokoi; T Kuramoto; M Sasa; T Serikawa
Journal:  J Neurochem       Date:  2000-06       Impact factor: 5.372

3.  Isozymes of phenylalanine hydroxylase.

Authors:  J A Barranger; P J Geiger; A Huzino; S P Bessman
Journal:  Science       Date:  1972-02-25       Impact factor: 47.728

4.  Epileptic seizures induced by N-acetyl-L-aspartate in rats: in vivo and in vitro studies.

Authors:  T Akimitsu; K Kurisu; R Hanaya; K Iida; Y Kiura; K Arita; H Matsubayashi; K Ishihara; K Kitada; T Serikawa; M Sasa
Journal:  Brain Res       Date:  2000-04-07       Impact factor: 3.252

5.  Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.

Authors:  C O Harding; M B Gillingham; K Hamman; H Clark; E Goebel-Daghighi; A Bird; D D Koeberl
Journal:  Gene Ther       Date:  2006-03       Impact factor: 5.250

6.  Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy.

Authors:  Rajwinder Dhami; Edward H Schuchman
Journal:  J Biol Chem       Date:  2003-10-13       Impact factor: 5.157

7.  Hypoosmolarity induces an increase of extracellular N-acetylaspartate concentration in the rat striatum.

Authors:  S E Davies; M Gotoh; D A Richards; T P Obrenovitch
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

8.  Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Authors:  Maria Traka; Robert L Wollmann; Sonia R Cerda; Jason Dugas; Ben A Barres; Brian Popko
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

9.  Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann-Pick disease.

Authors:  Hee-Kyung Jin; Edward H Schuchman
Journal:  Mol Ther       Date:  2003-12       Impact factor: 11.454

10.  Treatment of Niemann-Pick disease type B by allogeneic bone marrow transplantation.

Authors:  A Vellodi; J R Hobbs; N M O'Donnell; B S Coulter; K Hugh-Jones
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-28
View more
  5 in total

1.  Biodistribution of Adeno-Associated Virus Serotype 5 Viral Vectors Following Intrathecal Injection.

Authors:  Kelsey R Pflepsen; Cristina D Peterson; Kelley F Kitto; Maureen S Riedl; R Scott McIvor; George L Wilcox; Lucy Vulchanova; Carolyn A Fairbanks
Journal:  Mol Pharm       Date:  2021-08-30       Impact factor: 5.364

2.  Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9.

Authors:  Jonathan Dashkoff; Eli P Lerner; Nhi Truong; Jacob A Klickstein; Zhanyun Fan; Dakai Mu; Casey A Maguire; Bradley T Hyman; Eloise Hudry
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-07       Impact factor: 6.698

Review 3.  Battling Neurodegenerative Diseases with Adeno-Associated Virus-Based Approaches.

Authors:  Olja Mijanović; Ana Branković; Anton Borovjagin; Denis V Butnaru; Evgeny A Bezrukov; Roman B Sukhanov; Anastasia Shpichka; Peter Timashev; Ilya Ulasov
Journal:  Viruses       Date:  2020-04-18       Impact factor: 5.048

4.  Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.

Authors:  Georg von Jonquieres; Ziggy H T Spencer; Benjamin D Rowlands; Claudia B Klugmann; Andre Bongers; Anne E Harasta; Kristina E Parley; Jennie Cederholm; Orla Teahan; Russell Pickford; Fabien Delerue; Lars M Ittner; Dominik Fröhlich; Catriona A McLean; Anthony S Don; Miriam Schneider; Gary D Housley; Caroline D Rae; Matthias Klugmann
Journal:  Acta Neuropathol       Date:  2017-11-07       Impact factor: 17.088

Review 5.  Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I.

Authors:  Rachele Penati; Francesca Fumagalli; Valeria Calbi; Maria Ester Bernardo; Alessandro Aiuti
Journal:  J Inherit Metab Dis       Date:  2017-05-30       Impact factor: 4.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.